MX2020009044A - Procedimiento in vitro para detectar disfuncion de la barrera intestinal en animales. - Google Patents

Procedimiento in vitro para detectar disfuncion de la barrera intestinal en animales.

Info

Publication number
MX2020009044A
MX2020009044A MX2020009044A MX2020009044A MX2020009044A MX 2020009044 A MX2020009044 A MX 2020009044A MX 2020009044 A MX2020009044 A MX 2020009044A MX 2020009044 A MX2020009044 A MX 2020009044A MX 2020009044 A MX2020009044 A MX 2020009044A
Authority
MX
Mexico
Prior art keywords
intestinal barrier
sample
animals
vitro method
protein marker
Prior art date
Application number
MX2020009044A
Other languages
English (en)
Inventor
Stefan Pelzer
Richard Ducatelle
Frank Thiemann
Monika Flügel
Immerseel Filip Van
Evy Goossens
Bart Devreese
Griet Debyser
Original Assignee
Evonik Operations Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evonik Operations Gmbh filed Critical Evonik Operations Gmbh
Publication of MX2020009044A publication Critical patent/MX2020009044A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • G01N33/54386—Analytical elements
    • G01N33/54387—Immunochromatographic test strips
    • G01N33/54388—Immunochromatographic test strips based on lateral flow
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
    • Y02A40/70—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in livestock or poultry

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La presente invención se refiere a un procedimiento in vitro para detectar la disfunción de la barrera intestinal en una población de aves, el procedimiento comprende las siguientes etapas: a) recolectar una muestra combinada de materia fecal obtenida de una población de aves y b) determinar la cantidad de al menos un marcador de proteína contenido en dicha muestra; en el que el al menos un marcador de proteína comprende o consiste en una proteína de fase aguda o un fragmento funcional de la misma, y en el que una cantidad aumentada de dicho al menos un marcador de proteína contenido en dicha muestra frente a una muestra de referencia indica disfunción de la barrera intestinal.
MX2020009044A 2018-03-02 2019-02-28 Procedimiento in vitro para detectar disfuncion de la barrera intestinal en animales. MX2020009044A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18159632 2018-03-02
PCT/EP2019/054939 WO2019166531A1 (en) 2018-03-02 2019-02-28 In vitro method for detecting intestinal barrier failure in animals

Publications (1)

Publication Number Publication Date
MX2020009044A true MX2020009044A (es) 2020-10-12

Family

ID=61569071

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020009044A MX2020009044A (es) 2018-03-02 2019-02-28 Procedimiento in vitro para detectar disfuncion de la barrera intestinal en animales.
MX2020009045A MX2020009045A (es) 2018-03-02 2019-02-28 Procedimiento in vitro para detectar disfuncion de la barrera intestinal en animales mediante la determinacion de ovotransferrina.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020009045A MX2020009045A (es) 2018-03-02 2019-02-28 Procedimiento in vitro para detectar disfuncion de la barrera intestinal en animales mediante la determinacion de ovotransferrina.

Country Status (11)

Country Link
US (2) US20210003592A1 (es)
EP (2) EP3759496A1 (es)
KR (2) KR20200128412A (es)
CN (2) CN111819444A (es)
AR (1) AR114423A1 (es)
BR (2) BR112020017969A2 (es)
CA (2) CA3092472A1 (es)
MX (2) MX2020009044A (es)
RU (2) RU2020129391A (es)
WO (2) WO2019166534A1 (es)
ZA (2) ZA202005887B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2944359T3 (es) 2017-05-12 2023-06-20 Evonik Operations Gmbh Procedimiento de detección de enfermedades inducidas por C. perfringens en una bandada de aves
MX2020009044A (es) * 2018-03-02 2020-10-12 Evonik Operations Gmbh Procedimiento in vitro para detectar disfuncion de la barrera intestinal en animales.

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0281251A3 (en) * 1987-02-04 1988-09-28 International Immunoassay Laboratories, Inc. A method for preparing a fecal sample composition for immunoassay testing
UA78486C2 (uk) * 1999-12-10 2007-04-10 Хемджен Корпорейшн Композиція для перорального введення птахам та тваринам для лікування або зниження ризику інфекції травного тракту (варіанти), її застосування (варіанти) та спосіб лікування або зниження ризику інфекцій травного тракту (варіанти)
PL213982B1 (pl) * 2001-07-27 2013-05-31 Nutricia Nv Zastosowanie fosfolipidów, triglicerydów i cholesterolu oraz kompozycja do podawania dojelitowego
WO2005001483A2 (en) * 2003-06-27 2005-01-06 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Methods for diagnisis and differential diagnosis of dementia disorders
US8252769B2 (en) * 2004-06-22 2012-08-28 N. V. Nutricia Intestinal barrier integrity
DE602005010712D1 (de) * 2004-07-28 2008-12-11 Hoffmann La Roche Insulinpromotor-faktor 1 als target/marker von beta-zellen-störung
US8741662B2 (en) * 2006-06-14 2014-06-03 The Johns Hopkin University Albumin-bound protein/peptide complex as a biomarker for disease
US20100267062A1 (en) * 2007-09-26 2010-10-21 Norbert Frey Osteopontin as Novel Prognostic Biomarker for Heart Failure
EP3067694A1 (en) * 2008-05-05 2016-09-14 Los Alamos National Security, LLC Lateral flow-based nucleic acid sample preparation device, integrated with passive fluid flow control
AU2010210537B2 (en) * 2009-02-06 2015-06-18 Astute Medical, Inc. Diagnosis and prognosis of renal injury and renal failure
IT1406051B1 (it) * 2010-08-05 2014-02-06 D M G Italia S R L Uso di hmgb1 come marcatore biologico di infiammazione intestinale umana, metodo non invasivo per la sua rilevazione in campioni fecali e kit relativo.
RU2472162C1 (ru) * 2011-05-04 2013-01-10 Государственное научное учреждение Всероссийский научно-исследовательский институт экспериментальной ветеринарии им. Я.Р. Коваленко Россельхозакадемии Способ серологической диагностики вирусных желудочно-кишечных инфекций крупного рогатого скота методом иммуноферментного анализа
CN107080847A (zh) * 2011-06-24 2017-08-22 森彻斯有限公司 细胞外靶向药物缀合物
EP2626705A1 (en) * 2012-02-13 2013-08-14 Institut d'Investigacions Biomédiques August Pi i Sunyer Use of the soluble form of AXL in the diagnosis and/or prognosis of heart failure syndrome
EP2828282B1 (en) * 2012-03-20 2017-12-27 Otago Innovation Limited Biomarkers
JP2016530529A (ja) * 2013-09-05 2016-09-29 ユニヴァーシティ ヘルス ネットワーク 病気に対する重篤若しくは致命的な反応及び／又は治療反応の早期決定のためのバイオマーカー
SI3177149T1 (sl) * 2014-08-06 2023-07-31 Envera Lic, Llc Sestavki bakterijske spore za industrijsko uporabo
WO2016029051A1 (en) * 2014-08-20 2016-02-25 Rhode Island Hospital Assessment of heart failure and arrhythmic risk stratification by measuring circulating hu proteins
EP3112474A1 (en) * 2015-06-29 2017-01-04 Evonik Degussa GmbH Method of detecting avian necrotic enteritis
CN105412319A (zh) * 2016-01-05 2016-03-23 邱钱勇 一种治疗慢性肾功能衰竭的中药制剂及其制备方法及应用
MX2020009044A (es) * 2018-03-02 2020-10-12 Evonik Operations Gmbh Procedimiento in vitro para detectar disfuncion de la barrera intestinal en animales.

Also Published As

Publication number Publication date
RU2020129391A (ru) 2022-03-09
CN111819444A (zh) 2020-10-23
AR114423A1 (es) 2020-09-02
RU2020129428A3 (es) 2022-03-09
WO2019166531A1 (en) 2019-09-06
US20210011027A1 (en) 2021-01-14
WO2019166534A1 (en) 2019-09-06
MX2020009045A (es) 2020-10-12
KR20200128412A (ko) 2020-11-12
RU2020129391A3 (es) 2022-03-09
KR20200128413A (ko) 2020-11-12
RU2770104C2 (ru) 2022-04-14
BR112020017971A2 (pt) 2020-12-22
BR112020017969A2 (pt) 2020-12-22
CA3092519A1 (en) 2019-09-06
ZA202005890B (en) 2022-12-21
CA3092472A1 (en) 2019-09-06
CN111801579A (zh) 2020-10-20
RU2020129428A (ru) 2022-03-09
US20210003592A1 (en) 2021-01-07
EP3759495A1 (en) 2021-01-06
ZA202005887B (en) 2022-03-30
EP3759496A1 (en) 2021-01-06

Similar Documents

Publication Publication Date Title
ES2572372T3 (es) Método de diagnóstico de enfermedades neurodegenerativas basado en la medición de los niveles o de la actividad de SIRT1
Kandulski et al. Proteinase-activated receptor-2 in the pathogenesis of gastroesophageal reflux disease
Reinardy et al. Aromatic naphthenic acids in oil sands process-affected water, resolved by GCxGC-MS, only weakly induce the gene for vitellogenin production in zebrafish (Danio rerio) larvae
Yamamoto et al. Vitellogenin levels and others biomarkers show evidences of endocrine disruption in fish species from Iguaçu River-Southern Brazil
BR112017004899A2 (pt) detecção de proteínas mal dobradas
MX2020009044A (es) Procedimiento in vitro para detectar disfuncion de la barrera intestinal en animales.
ECSP088081A (es) Detección de un antigeno diana independientemente de la presencia o ausencia de un anticuerpo terapéutico correspondiente
PH12015502849B1 (en) Biomarkers for cognitive dysfunction diseases and method for detecting cognitive dysfunction disease using biomarkers
BRPI0810724A2 (pt) Método e sistema para extrair e separar um soluto de uma composição insolúvel.
ES2528321T3 (es) Detección de a-fucosilación en anticuerpos
MX2016013261A (es) Metodo para la cuantificacion de huevos de parasitos en las heces.
BRPI0607350A2 (pt) método para detecção da presença ou quantidade de uma proteìna erroneamente duplicada em uma amostra e kit
Karouna-Renier et al. Assessment of mitochondrial DNA damage in little brown bats (Myotis lucifugus) collected near a mercury-contaminated river
ES2530734T3 (es) Biomarcador en suero bioquímico
BR112019005167A2 (pt) método e kit para analisar uma amostra
BR112019005172A2 (pt) método e kit para analisar uma amostra
BRPI0814250B8 (pt) dispositivo, kit e método para captura e detecção de antígeno de ancilóstomo
Muñoz-Sáez et al. Analysis of β-N-methylamino-L-alanine (L-BMAA) neurotoxicity in rat cerebellum
AR083259A1 (es) Cuantificacion y caracterizacion de los alergenos
French et al. FAT10 knock out mice livers fail to develop Mallory–Denk bodies in the DDC mouse model
AR105379A1 (es) Dispositivo para detectar proteínas mal plegadas y sus métodos de uso
Dong et al. Modification of the plasma complement protein profile by exogenous estrogens is indicative of a compromised immune competence in marine medaka (Oryzias melastigma)
AR087654A1 (es) METODO DIAGNOSTICO DE ANIMALES VACUNADOS CON PESTIVIRUS QUIMERICO EN EL CUAL LA PROTEINA Eʳⁿˢ DEL VIRUS DE LA DIARREA VIRAL BOVINA (BVDV) ES REMPLAZADA POR PROTEINA Eʳⁿˢ DE PESTIVIRUS DE ANTILOPE AMERICANO
CL2008000062A1 (es) Sistema portatil mediante el cual se puede determinar la calidad de un trozo de carne sin necesidad de manipularla, que permite la captura de imagenes para su posterior procesamiento; y metodo asociado.
BRPI0820567A2 (pt) Método para o enriquecimento seletivo e/ou separação de proteínas e/ou peptídeos pós-translacionalmente modificados de uma amostra, e, uso de um método.